|Day Low/High||45.69 / 46.56|
|52 Wk Low/High||44.30 / 63.69|
Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.
I am reluctant to call this a breakout, and am willing to sit back and wait.
The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...
Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.
Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
A couple of quick wins, a hedge/fade that didn't work, and 2 triggers not firing.
It's the most random day of the week, with stocks all over the map.
It's finally seeing a little light and is still worth owning.
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
The stock will eventually rebase, but we don't know where or when.
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...
Interpreting "K-M curves" correctly is an important tool for biotech investors.
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
Stocks in the health care sector seem to have no underpinnings whatsoever.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.